Webinar
"Non-Alcoholic Fatty Liver Disease (NAFLD): Epidemiology, Pathophysiology, Diagnosis"

Non-Alcoholic Fatty Liver Disease (NAFLD): Epidemiology, Pathophysiology, Diagnosis

Order Code: 26ADAM101818

Presenter Mikhael Adams BSc ND
Date Thursday, October 18, 2018
Time 8:00 PM - 9:30 PM EST
5:00 PM - 6:30 PM PST
Topics Holistic Modalities
Credits (CEU) "Continuing Education Credits
Eligible for Cono Category B Credits (ON)
1.5 CNPBC Hours (BC)
1.5 SANP Hours (SK)
1.5 MNA Hours (MB)
1.5 Hours (AB)
1.5 CEUs (WA)
"

Current research indicates that the prevalence and impact of NAFLD continues to increase. The term NAFLD encompasses a wide range of conditions marked by an accumulation of fat in the liver. NASH represents the more severe end of the spectrum of non-alcoholic fatty liver disease and differs from the simple accumulation of fat in the liver, which has a more vague set of symptoms and diagnostic criteria. However, NAFLD is associated with higher levels of glycated haemoglobin, triglyceride to high density lipoprotein cholesterol ratio, insulin resistance, and liver enzymes (alanine aminotransferase, aspartate aminotransferase, and glutamyltransferase). NAFLD is universally considered as the hepatic manifestation of the metabolic syndrome (MS), and insulin resistance is regarded as its key pathophysiological hallmark. Symptoms of NAFLD are vague, but it has a strong association with central obesity, reduced glucose tolerance, type 2 diabetes mellitus, arterial hypertension and hypertriglyceridaemia.

Overview
Current research indicates that the prevalence and impact of NAFLD continues to increase. The term NAFLD encompasses a wide range of conditions marked by an accumulation of fat in the liver. NASH represents the more severe end of the spectrum of non-alcoholic fatty liver disease and differs from the simple accumulation of fat in the liver, which has a more vague set of symptoms and diagnostic criteria. However, NAFLD is associated with higher levels of glycated haemoglobin, triglyceride to high density lipoprotein cholesterol ratio, insulin resistance, and liver enzymes (alanine aminotransferase, aspartate aminotransferase, and glutamyltransferase). NAFLD is universally considered as the hepatic manifestation of the metabolic syndrome (MS), and insulin resistance is regarded as its key pathophysiological hallmark. Symptoms of NAFLD are vague, but it has a strong association with central obesity, reduced glucose tolerance, type 2 diabetes mellitus, arterial hypertension and hypertriglyceridaemia.

KEY LEARNING HIGHLIGHTS
Brief review of current epidemiology
Pathophysiology Diagnosis
Lifestyle and dietary modifications for patient support
Support for associated symptoms
Read More Read Less
Reviews

Leave a review

Welcome to the Seroyal Continuing Medical Education (CME) program for physicians and other healthcare professionals. Our live programming, including courses, one-day intensives, webinars, teleconferences and teleconference series, are CME tools that enable healthcare professionals to come together throughout North America in the pursuit of lifelong learning in a manner that is interactive, accessible and affordable.

Lead by internationally recognized experts in natural medicine and science, our programs are designed to support optimized case management and patient care since 1989. Our team is committed to providing world-class, clinically relevant information that can be immediately integrated with existing modalities for a complete, holistic approach.

         

Seminars

Our Seminars provide extensive clinical experience and solidified reference materials to expand your therapeutic capabilities and help support your practice.

Teleconferences

Our live Teleconferences and Teleconference Series are key learning tools, allowing practitioners to join our community from the convenience of your home or office.

Webinars

Our Webinars enable practitioners to participate in live interactive sessions, helping to make the life-long journey of learning both accessible and convenient.